As we reflect on 2023 and make predictions for 2024, it is remarkable the number of significant events occurring this past year that will be impactful for the activities of the life sciences industry going forward. Although...more
1/26/2024
/ Acquisitions ,
Amgen v Sanofi ,
Antitrust Division ,
Artificial Intelligence ,
Biden Administration ,
Biosimilars ,
Chevron Deference ,
Clawbacks ,
Clinical Trials ,
Compensation ,
Compliance ,
Corporate Integrity Agreement ,
Criminal Prosecution ,
Data Preservation ,
Department of Health and Human Services (HHS) ,
Department of Justice (DOJ) ,
Drug Pricing ,
Enforcement ,
EU ,
Executive Orders ,
False Claims Act (FCA) ,
Federal Trade Commission (FTC) ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Investigations ,
Life Sciences ,
Mergers ,
Mobile Devices ,
OPDP ,
Pharmaceutical Industry ,
Pilot Programs ,
Privacy Laws ,
Proposed Rules ,
Risk Management ,
Section 340B ,
Self-Disclosure Requirements ,
Voluntary Disclosure
Pharma and Life Sciences Investigations and Prosecutions: The First Two Years of the Biden Administration -
With the two-year mark of the Biden presidency looming, the administration’s approach to prosecuting and...more
1/12/2023
/ Biden Administration ,
Centers for Medicare & Medicaid Services (CMS) ,
Corporate Governance ,
Criminal Prosecution ,
Digital Health ,
Enforcement ,
False Claims Act (FCA) ,
Life Sciences ,
Medicare Advantage ,
OPDP ,
Pharmaceutical Industry ,
Privacy Laws ,
Stocks ,
Telehealth